Overview

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ledipasvir
Ribavirin